These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

487 related articles for article (PubMed ID: 12827536)

  • 21. Voriconazole: therapeutic review of a new azole antifungal.
    Herbrecht R
    Expert Rev Anti Infect Ther; 2004 Aug; 2(4):485-97. PubMed ID: 15482215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro interactions between antifungals and immunosuppressants against Aspergillus fumigatus isolates from transplant and nontransplant patients.
    Steinbach WJ; Singh N; Miller JL; Benjamin DK; Schell WA; Heitman J; Perfect JR
    Antimicrob Agents Chemother; 2004 Dec; 48(12):4922-5. PubMed ID: 15561883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fungal infection of cystic fibrosis patients - single center experience.
    Garczewska B; Jarzynka S; Kuś J; Skorupa W; Augustynowicz-Kopeć E
    Pneumonol Alergol Pol; 2016; 84(3):151-9. PubMed ID: 27238177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Disseminated Scedosporium apiospermum infection in renal transplant recipient: long-term successful treatment with voriconazole: a case report.
    Rogasi PG; Zanazzi M; Nocentini J; Fantoni E; Trotta M; Faggi E; Fontanelli A; Bertoni E; Salvadori M; Leoncini F
    Transplant Proc; 2007; 39(6):2033-5. PubMed ID: 17692684
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Experience with voriconazole in invasive aspergillosis].
    Thiel E; Schwartz S
    Mycoses; 2003; 46 Suppl 2():3-7. PubMed ID: 15055137
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome.
    Husain S; Muñoz P; Forrest G; Alexander BD; Somani J; Brennan K; Wagener MM; Singh N
    Clin Infect Dis; 2005 Jan; 40(1):89-99. PubMed ID: 15614697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients.
    Veroux M; Corona D; Gagliano M; Sorbello M; Macarone M; Cutuli M; Giuffrida G; Morello G; Paratore A; Veroux P
    Transplant Proc; 2007; 39(6):1838-40. PubMed ID: 17692627
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aspergillosis due to voriconazole highly resistant Aspergillus fumigatus and recovery of genetically related resistant isolates from domiciles.
    van der Linden JW; Camps SM; Kampinga GA; Arends JP; Debets-Ossenkopp YJ; Haas PJ; Rijnders BJ; Kuijper EJ; van Tiel FH; Varga J; Karawajczyk A; Zoll J; Melchers WJ; Verweij PE
    Clin Infect Dis; 2013 Aug; 57(4):513-20. PubMed ID: 23667263
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cardiac invasive aspergillosis in a heart transplant recipient].
    Eworo A; Muñoz P; Yáñez JF; Palomo J; Guembe P; Roda J; Valerio M; Guinea J; Bouza E
    Rev Iberoam Micol; 2011; 28(3):134-8. PubMed ID: 21700234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies.
    Espinel-Ingroff A; Johnson E; Hockey H; Troke P
    J Antimicrob Chemother; 2008 Mar; 61(3):616-20. PubMed ID: 18222957
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro susceptibility testing of Aspergillus spp. against voriconazole, itraconazole, posaconazole, amphotericin B and caspofungin.
    Shi JY; Xu YC; Shi Y; Lü HX; Liu Y; Zhao WS; Chen DM; Xi LY; Zhou X; Wang H; Guo LN
    Chin Med J (Engl); 2010 Oct; 123(19):2706-9. PubMed ID: 21034656
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superiority of voriconazole over amphotericin B in the treatment of invasive aspergillosis after heart transplantation.
    Wieland T; Liebold A; Jagiello M; Retzl G; Birnbaum DE
    J Heart Lung Transplant; 2005 Jan; 24(1):102-4. PubMed ID: 15653389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro activity (MIC and MFC) of voriconazole, amphotericin B, and itraconazole against 192 filamentous fungi: the GISIA-2 study.
    Morace G; Drago M; Scaltrito MM; Conti S; Fanti F; Polonelli L;
    J Chemother; 2007 Oct; 19(5):508-13. PubMed ID: 18073149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Voriconazole - applications and perspectives].
    Ruhnke M
    Mycoses; 2002; 45 Suppl 3():42-7. PubMed ID: 12690971
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp.
    Lewis RE; Wiederhold NP; Klepser ME
    Antimicrob Agents Chemother; 2005 Mar; 49(3):945-51. PubMed ID: 15728887
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [symbol: see text]Caspofungin and [symbol: see text]voriconazole for fungal infections.
    Drug Ther Bull; 2004 Jan; 42(1):5-8. PubMed ID: 14768298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
    Walsh TJ; Lutsar I; Driscoll T; Dupont B; Roden M; Ghahramani P; Hodges M; Groll AH; Perfect JR
    Pediatr Infect Dis J; 2002 Mar; 21(3):240-8. PubMed ID: 12005089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin.
    Al-Badriyeh D; Leung L; Davies GE; Stewart K; Kong D
    Ann Pharmacother; 2009 Jun; 43(6):1139-42. PubMed ID: 19435962
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activity of voriconazole (UK-109,496) against clinical isolates of Aspergillus species and its effectiveness in an experimental model of invasive pulmonary aspergillosis.
    Murphy M; Bernard EM; Ishimaru T; Armstrong D
    Antimicrob Agents Chemother; 1997 Mar; 41(3):696-8. PubMed ID: 9056016
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.